Bristol-Myers Squibb Company PFD CONV 2 (BMYMP)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) with AI Score 50/100 (Hold). Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, including cardiovascular, cancer, and immune disorders. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) Healthcare & Pipeline Overview
Bristol-Myers Squibb PFD CONV 2 (BMYMP) is a pharmaceutical company focused on discovering, developing, and marketing drugs, particularly in immuno-oncology. With a 14.6% profit margin and a 4.17% dividend yield, the company generates approximately 70% of its revenue from the U.S. market, operating within the broader healthcare sector.
Investment Thesis
Bristol-Myers Squibb PFD CONV 2 presents a mixed investment thesis. The company's strong presence in immuno-oncology and a solid 14.6% profit margin offer potential upside. A dividend yield of 4.17% provides income for investors. However, the company's high dependence on the U.S. market (70% of sales) exposes it to regulatory and market risks specific to that region. The company's beta of 0.27 suggests lower volatility compared to the broader market. Upcoming catalysts in their drug pipeline and potential expansion into new markets could drive future growth. Investors should carefully weigh these factors, considering the competitive landscape and potential regulatory changes.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $1589.46B indicates a large and established company within the pharmaceutical industry.
- P/E ratio of 17.28 suggests the company is reasonably valued compared to its earnings.
- Profit margin of 14.6% demonstrates strong profitability in the competitive pharmaceutical market.
- Gross margin of 67.6% reflects efficient cost management in drug manufacturing and sales.
- Dividend yield of 4.17% provides a substantial return to investors, making it attractive for income-seeking portfolios.
Competitors & Peers
Strengths
- Strong presence in immuno-oncology.
- High gross margin of 67.6%.
- Significant market capitalization.
- Established brand reputation.
Weaknesses
- High dependence on the U.S. market.
- Exposure to drug pricing pressures.
- Reliance on patent protection.
- Potential for biosimilar competition.
Catalysts
- Potential FDA approval of new drug candidates in the pipeline.
- Expansion into new geographic markets, particularly in emerging economies.
- Strategic partnerships and collaborations with other pharmaceutical companies.
- Results from ongoing clinical trials for key drug candidates.
- Increasing demand for immuno-oncology therapies.
Risks
- Regulatory changes in the U.S. healthcare system could impact drug pricing and reimbursement.
- Increasing competition from other pharmaceutical companies in key therapeutic areas.
- Patent expirations could lead to generic competition and reduced revenue.
- Economic downturns could affect healthcare spending and demand for pharmaceutical products.
- Product liability lawsuits and other legal challenges.
Growth Opportunities
- Expansion into Emerging Markets: Bristol-Myers Squibb has the opportunity to expand its presence in emerging markets, such as Asia-Pacific and Latin America. These regions are experiencing rapid economic growth and increasing healthcare spending, creating a significant demand for pharmaceutical products. By establishing strategic partnerships and tailoring its product offerings to local needs, Bristol-Myers Squibb can tap into these high-growth markets and diversify its revenue streams. This expansion could contribute significantly to revenue growth over the next 3-5 years, with the emerging markets pharmaceutical sector estimated to reach hundreds of billions of dollars by 2030.
- Development of Novel Therapies in Oncology: Bristol-Myers Squibb can capitalize on its expertise in immuno-oncology by developing novel therapies for various types of cancer. The global oncology market is projected to reach hundreds of billions of dollars by 2028, driven by advancements in cancer research and increasing incidence rates. By investing in research and development and pursuing strategic collaborations, Bristol-Myers Squibb can bring innovative cancer treatments to market and capture a significant share of this growing market. The timeline for this growth opportunity is dependent on clinical trial outcomes and regulatory approvals, typically spanning several years.
- Strategic Acquisitions and Partnerships: Bristol-Myers Squibb can pursue strategic acquisitions and partnerships to expand its product portfolio and gain access to new technologies. The pharmaceutical industry is characterized by frequent mergers and acquisitions, as companies seek to strengthen their competitive position and diversify their offerings. By acquiring companies with promising drug candidates or innovative technologies, Bristol-Myers Squibb can accelerate its growth and enhance its long-term prospects. The timing and impact of these acquisitions are difficult to predict, but they can significantly alter the company's growth trajectory.
- Focus on Personalized Medicine: Bristol-Myers Squibb can leverage advancements in genomics and diagnostics to develop personalized medicine solutions tailored to individual patients. Personalized medicine involves using a patient's genetic information to select the most effective treatment options, improving outcomes and reducing side effects. By investing in personalized medicine research and developing companion diagnostics, Bristol-Myers Squibb can differentiate its products and capture a growing share of the market for targeted therapies. The personalized medicine market is expected to grow substantially over the next decade, driven by technological advancements and increasing adoption by healthcare providers.
- Expansion of Digital Health Solutions: Bristol-Myers Squibb can expand its offerings in digital health solutions, such as mobile apps and wearable devices, to improve patient engagement and adherence to treatment regimens. Digital health solutions can provide patients with personalized support, track their progress, and facilitate communication with healthcare providers. By developing and integrating digital health solutions into its product offerings, Bristol-Myers Squibb can enhance patient outcomes and strengthen its relationships with healthcare providers. The digital health market is experiencing rapid growth, driven by increasing adoption of mobile technology and growing demand for remote patient monitoring.
Opportunities
- Expansion into emerging markets.
- Development of novel therapies in oncology.
- Strategic acquisitions and partnerships.
- Focus on personalized medicine.
Threats
- Regulatory changes in the U.S. healthcare system.
- Increasing competition from other pharmaceutical companies.
- Patent expirations.
- Economic downturns affecting healthcare spending.
Competitive Advantages
- Patent protection for its innovative drugs provides a period of market exclusivity.
- Strong brand reputation and established relationships with healthcare providers.
- Extensive research and development capabilities enable the company to develop new products.
- Regulatory expertise in navigating the complex drug approval process.
About BMYMP
Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for patients with serious diseases. The company's history is rooted in the late 19th century, evolving through mergers and acquisitions to become a leader in the pharmaceutical industry. Bristol-Myers Squibb's primary focus is on therapeutic areas such as oncology, hematology, immunology, cardiovascular, and neuroscience. Its key products include innovative treatments for various cancers, immune disorders, and cardiovascular conditions. The company operates globally, with a significant presence in the United States, which accounts for approximately 70% of its total sales. Bristol-Myers Squibb competes with other major pharmaceutical companies, focusing on research and development to maintain its competitive edge and expand its portfolio of innovative medicines. The company employs approximately 34,100 individuals and is headquartered in Princeton, New Jersey.
What They Do
- Discovers and develops pharmaceutical products.
- Markets and sells prescription medications.
- Focuses on therapeutic areas like oncology, immunology, and cardiovascular diseases.
- Conducts clinical trials to evaluate the safety and efficacy of new drugs.
- Manufactures pharmaceutical products.
- Engages in research and development to identify new drug targets and therapies.
- Works with regulatory agencies to obtain approval for new drugs.
Business Model
- Develops and patents innovative pharmaceutical products.
- Generates revenue through the sale of prescription medications.
- Invests heavily in research and development to create new products.
- Markets products to healthcare providers and patients.
Industry Context
Bristol-Myers Squibb operates in the highly competitive drug manufacturing industry, characterized by intense research and development, stringent regulatory requirements, and patent protection. The global pharmaceutical market is projected to reach trillions of dollars by 2026, driven by an aging population and increasing prevalence of chronic diseases. Bristol-Myers Squibb competes with major players like AZNCF, BAYRY, CHGCF, CHGCY, and GLAXF, all vying for market share in key therapeutic areas. The industry is also influenced by factors such as drug pricing pressures, biosimilar competition, and healthcare reforms.
Key Customers
- Patients who require prescription medications for various diseases.
- Healthcare providers, including physicians, hospitals, and clinics.
- Pharmacies that dispense prescription medications.
- Government and private healthcare insurers.
Financials
Chart & Info
Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) stock price: Price data unavailable
Latest News
-
Stocks That Set New 52-Week Lows Friday Morning
· Aug 2, 2019
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BMYMP.
Price Targets
Wall Street price target analysis for BMYMP.
MoonshotScore
What does this score mean?
The MoonshotScore rates BMYMP's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Christopher S. Boerner
CEO
Christopher S. Boerner is the Chief Executive Officer of Bristol-Myers Squibb. Prior to this role, he held various leadership positions within the company, including Chief Operating Officer and Executive Vice President, Chief Commercial Officer. Boerner has extensive experience in the pharmaceutical industry, with a background in commercial operations, strategy, and business development. He holds a Ph.D. in Pharmacology from the University of North Carolina at Chapel Hill and an MBA from Harvard Business School.
Track Record: Since becoming CEO, Christopher S. Boerner has focused on driving innovation and growth within Bristol-Myers Squibb. Key initiatives include expanding the company's pipeline of new drugs, strengthening its presence in key therapeutic areas, and enhancing its operational efficiency. Boerner has also emphasized the importance of strategic partnerships and acquisitions to accelerate the company's growth and expand its market reach.
BMYMP OTC Market Information
The OTC Other tier represents the lowest tier of over-the-counter (OTC) securities. Companies in this tier often have limited financial disclosure and may not meet minimum listing requirements of major exchanges like the NYSE or NASDAQ. These securities can include a wide range of companies, from those in early stages of development to distressed or defunct entities. Investing in OTC Other securities carries a higher degree of risk due to the lack of regulatory oversight and potential for fraud or manipulation. Investors should conduct thorough due diligence before considering investments in this tier.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing due to lack of transparency.
- Low trading volume and wide bid-ask spreads can make it difficult to buy or sell shares.
- Potential for fraud or manipulation due to limited regulatory oversight.
- Higher risk of company failure or delisting compared to securities listed on major exchanges.
- Limited access to company information and management.
- Verify the company's registration and regulatory filings.
- Review the company's financial statements, if available.
- Assess the company's business model and competitive landscape.
- Evaluate the company's management team and track record.
- Check for any legal or regulatory issues.
- Understand the risks associated with investing in OTC securities.
- Consult with a financial advisor before making any investment decisions.
- Company has a verifiable business address and contact information.
- Management team has relevant experience and a proven track record.
- Company has a clear business plan and strategy.
- Company has a history of operating in its industry.
- Company has positive reviews or testimonials from customers or partners.
Bristol-Myers Squibb Company PFD CONV 2 Healthcare Stock: Key Questions Answered
What does Bristol-Myers Squibb Company PFD CONV 2 do?
Bristol-Myers Squibb discovers, develops, and markets a range of pharmaceutical products across several key therapeutic areas, including oncology, immunology, cardiovascular, and neuroscience. The company's primary focus is on developing innovative treatments for serious diseases, with a significant emphasis on immuno-oncology. Bristol-Myers Squibb operates globally, with a substantial portion of its revenue generated in the United States. The company invests heavily in research and development to maintain a competitive edge and expand its portfolio of innovative medicines.
What do analysts say about BMYMP stock?
Analyst consensus for Bristol-Myers Squibb PFD CONV 2 is currently mixed, reflecting the complexities of the pharmaceutical industry and the company's specific challenges and opportunities. Key valuation metrics such as the P/E ratio of 17.28 and the dividend yield of 4.17% are closely monitored. Growth considerations include the company's pipeline of new drugs, its expansion into emerging markets, and potential regulatory changes. Analysts also consider the competitive landscape and the impact of patent expirations on future revenue. This is a neutral summary of analyst sentiment based on available data.
What are the main risks for BMYMP?
Bristol-Myers Squibb faces several key risks, including regulatory changes in the U.S. healthcare system, which could impact drug pricing and reimbursement. Increasing competition from other pharmaceutical companies, particularly in the immuno-oncology space, poses a significant threat. Patent expirations could lead to generic competition and reduced revenue. Economic downturns could affect healthcare spending and demand for pharmaceutical products. Additionally, the company is exposed to product liability lawsuits and other legal challenges, which could result in significant financial losses.
What are the key growth opportunities for BMYMP in healthcare?
Bristol-Myers Squibb has several key growth opportunities within the healthcare sector. Expansion into emerging markets, such as Asia-Pacific and Latin America, offers significant potential for revenue growth. The development of novel therapies in oncology, particularly in areas with unmet medical needs, represents another important growth driver. Strategic acquisitions and partnerships can expand the company's product portfolio and access new technologies. A focus on personalized medicine and the development of digital health solutions can also enhance patient outcomes and strengthen the company's competitive position.
What is Bristol-Myers Squibb Company PFD CONV 2's drug pipeline status?
Bristol-Myers Squibb's clinical pipeline includes drug candidates in various stages of development, spanning key therapeutic areas such as oncology, immunology, cardiovascular, and neuroscience. The pipeline includes both small molecule drugs and biologics, targeting a range of diseases and conditions. Upcoming catalysts include data readouts from ongoing clinical trials, regulatory submissions for new drug approvals, and potential commercial launches of new products. The company's pipeline is a critical driver of future growth and innovation, and its progress is closely monitored by investors and analysts.
What are the key factors to evaluate for BMYMP?
Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) currently holds an AI score of 50/100, indicating moderate score. Key strength: Strong presence in immuno-oncology. Primary risk to monitor: Regulatory changes in the U.S. healthcare system could impact drug pricing and reimbursement. This is not financial advice.
How frequently does BMYMP data refresh on this page?
BMYMP prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven BMYMP's recent stock price performance?
Recent price movement in Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Strong presence in immuno-oncology. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- OTC data may be less reliable than exchange-listed data.
- AI analysis pending, limiting insight.